Elfabrio (PEGunigalsidase Alfa-Iwxj) Patent Expiration, LOE Window & CMS Spending

Elfabrio (PEGunigalsidase Alfa-Iwxj) by Chiesi Farmaceutici Spa: Biologic BLA (Purple Book Regime), 0 AB generics, $8.2M 2024 CMS Part D & Medicaid spend, and $41,351 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorChiesi Farmaceutici Spa
FDA Application & PathwayB761161 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$8.2M
2024 Medicare Part D Spend$5.2M
2024 Medicaid Spend$3.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($41,351 intro WAC)